Daphne Koller on AI in Drug Discovery: Structure Over Compute
ziv_ravid · x · 2026-08-20
Daphne Koller, founder of insitro, discusses the application of AI in biology and drug discovery. While acknowledging the 'Bitter Lesson', she notes that biology lacks sufficient data, making structured knowledge essential. She explains the high failure rate in drug discovery (90% fail in the clinic), often due to wrong targets rather than bad molecules. The conversation also covers the limits of agents in wet labs, the challenge of biological foundation models, and insights from GLP-1 drugs.
More from Apps
- AI portfolio up 257% beats S&P 500 as Claude rebalances holdings — alejandroll10 · 2026-08-20
- GrokBot Hype in Silicon Valley: Cloud Multi-Agent Collaboration Boosts Productivity 100x — 新智元 · 2026-08-20
- Claude's Skill Creator Wins for Detail: Tests and Iterates vs ChatGPT's Magic — emollick · 2026-08-20
- Critique on AI coding UI: need tmux-style panes for multiple chat threads — madhavsinghal_ · 2026-08-20
- Open Source Checkmate Tracks Server Hardware and Response Times — tom_doerr · 2026-08-20
- Reddit User Shares: ChatGPT Helps Manage Anxiety Better Than Therapy — starlightsparkle444 · 2026-08-20